|
1
|
du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: A
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: By the arbeitsgemeinschaft gynaekologische
onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe
d'investigateurs nationaux pour les etudes des cancers de l'Ovaire
(GINECO). Cancer. 115:1234–1244. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953.
2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bottoni P and Scatena R: The role of CA
125 as tumor marker: biochemical and clinical aspects. Adv Exp Med
Biol. 867:229–244. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sölétormos G, Duffy MJ, Othman Abu Hassan
S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon
CM, Bonfrer JM, Petersen PH, et al: Clinical use of cancer
biomarkers in epithelial ovarian cancer updated guidelines from the
European group on tumor markers. Int J Gynecol Cancer. 26:43–51.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Menczer J, Ben-Shem E, Golan A and Levy T:
The significance of normal pretreatment levels of CA125 (<35
U/ml) in epithelial ovarian carcinoma. Rambam Maimonides Med J.
6(e0005)2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fader AN, Java J, Krivak TC, Bristow RE,
Tergas AI, Bookman MA, Armstrong DK, Tanner EJ and Gershenson DM:
The prognostic significance of pre- and post-treatment CA-125 in
grade 1 serous ovarian carcinoma: A gynecologic Oncology Group
study. Gynecol Oncol. 132:560–565. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Markman M, Federico M, Liu PY, Hannigan E
and Alberts D: Significance of early changes in the serum CA-125
antigen level on overall survival in advanced ovarian cancer.
Gynecol Oncol. 103:195–198. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yuan Q, Song J, Yang W, Wang H, Huo Q,
Yang J, Yu X, Liu Y, Xu C and Bao H: The effect of CA125 on
metastasis of ovarian cancer: Old marker new function. Oncotarget.
8:50015–50022. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Randall LM, Sill MW, Burger RA, Monk BJ,
Buening B and Sorosky JI: Predictive value of serum CA-125 levels
in patients with persistent or recurrent epithelial ovarian cancer
or peritoneal cancer treated with bevacizumab on a Gynecologic
Oncology Group phase II trial. Gynecol Oncol. 124:563–568.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chi DS, Venkatraman ES, Masson V and
Hoskins WJ: The ability of preoperative serum CA-125 to predict
optimal primary tumor cytoreduction in stage III epithelial ovarian
carcinoma. Gynecol Oncol. 77:227–231. 2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ghisoni E, Katsaros D, Maggiorotto F,
Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M,
Genta S, et al: A predictive score for optimal cytoreduction at
interval debulking surgery in epithelial ovarian cancer: A two-
centers experience. J Ovarian Res. 11(42)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Memarzadeh S, Lee SB, Berek JS and
Farias-Eisner R: CA-125 levels are a weak predictor of optimally
cytoreductive surgery in patients with advance epithelial ovarian
cancer. Int J Gynecol Cancer. 13:120–124. 2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cooper BC, Sood AK, Davis CS, Ritchie JM,
Sorosky JI, Anderson B and Buller RE: Preoperative CA 125 levels:
An independent prognostic factor for epithelial ovarian cancer.
Obstet Gynecol. 100:59–64. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brockbank EC, Ind TE, Barton DP, Shepherd
JH, Gore ME, A'Hern R and Bridges JE: Preoperative predictors of
suboptimal primary surgical cytoreduction in women with clinical
evidence of advanced primary epithelial ovarian cancer. Int J
Gynecol Cancer. 14:42–50. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gill SE, McGree ME, Weaver AL, Cliby WA
and Langstraat CL: Optimizing the treatment of ovarian cancer:
Neoadjuvant chemotherapy and interval debulking versus primary
debulking surgery for epithelial ovarian cancers likely to have
suboptimal resection. Gynecol Oncol. 144:266–273. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Suidan RS, Ramirez PT, Sarasohn DM,
Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic
O, Long Roche KC, et al: A multicenter assessment of the ability of
preoperative computed tomography scan and CA-125 to predict gross
residual disease at primary debulking for advanced epithelial
ovarian cancer. Gynecol Oncol. 145:27–31. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Prat J: FIGO Committee on Gynecologic
Oncology. Staging classification for cancer of the ovary, fallopian
tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wimberger P, Lehmann N, Kimmig R, Burges
A, Meier W and Du Bois A: Arbeitsgemeinschaft Gynaekologische
Onkologie Ovarian Cancer Study Group. Prognostic factors for
complete debulking in advanced ovarian cancer and its impact on
survival. An exploratory analysis of a prospectively randomized
phase III study of the Arbeitsgemeinschaft gynaekologische
onkologie ovarian cancer study group (AGOOVAR). Gynecol Oncol.
106:69–74. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Suidan RS, Ramirez PT, Sarasohn DM,
Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka
M, et al: A multicenter prospective trial evaluating the ability of
preoperative computed tomography scan and serum CA-125 to predict
suboptimal cytoreduction at primary debulking surgery for advanced
ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol.
134:455–461. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Barlow TS, Przybylski M, Schilder JM,
Moore DH and Look KY: The utility of presurgical CA125 to predict
optimal tumor cytoreduction of epithelial ovarian cancer. Int J
Gynecol Cancer. 16:496–500. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Morales-Vásquez F, Pedernera E,
Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas
S, Silva-Ayala R, Almaraz M and Méndez C: High levels of
pretreatment CA125 are associated to improved survival in high
grade serous ovarian carcinoma. J Ovarian Res. 9(41)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Babic A, Cramer DW, Kelemen LE, Köbel M,
Steed H, Webb PM, Johnatty SE, deFazio A, Lambrechts D, Goodman MT,
et al: Predictors of pretreatment CA125 at ovarian cancer
diagnosis: A pooled analysis in the ovarian cancer association
consortium. Cancer Causes Control. 28:459–468. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zorn KK, Tian C, McGuire WP, Hoskins WJ,
Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D and Armstrong
DK: The prognostic value of pretreatment CA 125 in patients with
advanced ovarian carcinoma: A Gynecologic Oncology Group study.
Cancer. 115:1028–1035. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chi DS, Zivanovic O, Palayekar MJ,
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown
CL and Barakat RR: A contemporary analysis of the ability of
preoperative serum CA-125 to predict primary cytoreductive outcome
in patients with advanced ovarian, tubal and peritoneal carcinoma.
Gynecol Oncol. 112:6–10. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bai H, Sha G, Xiao M, Gao H, Cao D, Yang
J, Chen J, Wang Y, Zhang Z and Shen K: The prognostic value of
pretreatment CA-125 levels and CA-125 normalization in ovarian
clear cell carcinoma: A two-academic-institute study. Oncotarget.
7:15566–15576. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lee M, Chang MY, Yoo H, Lee KE, Chay DB,
Cho H, Kim S, Kim YT and Kim JH: Clinical significance of CA125
level after the first cycle of chemotherapy on survival of patients
with advanced ovarian cancer. Yonsei Med J. 57:580–587.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Angioli R, Plotti F, Capriglione S, Aloisi
A, Montera R, Luvero D, Miranda A, Cafà EV, Damiani P and
Benedetti-Panici P: Can the preoperative HE4 level predict optimal
cytoreduction in patients with advanced ovarian carcinoma? Gynecol
Oncol. 128:579–583. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Braicu EI, Fotopoulou C, Van Gorp T,
Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S,
Zeillinger R, et al: Preoperative HE4 expression in plasma predicts
surgical outcome in primary ovarian cancer patients: Results from
the OVCAD study. Gynecol Oncol. 128:245–251. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gąsiorowska E, Michalak M, Warchoł W,
Lemańska A, Jasiński P, Spaczyński M and Nowak-Markwitz E: Clinical
application of HE4 and CA125 in ovarian cancer type I and type II
detection and differential diagnosis. Ginekol Pol. 86:88–93.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sioulas VD, Schiavone MB, Kadouri D,
Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA,
Sonoda Y, Gardner GJ, et al: Optimal primary management of bulky
stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are
the only options complete gross resection at primary debulking
surgery or neoadjuvant chemotherapy? Gynecol Oncol. 145:15–20.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick
AM, Lu KH, Sood AK, Coleman RL and Ramirez PT: Predictors of
optimal cytoreduction in patients with newly diagnosed
advanced-stage epithelial ovarian cancer: Time to incorporate
laparoscopic assessment into the standard of care. Gynecol Oncol.
137:553–558. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Karlsen MA, Fagö-Olsen C, Høgdall E,
Schnack TH, Christensen IJ, Nedergaard L, Lundvall L, Lydolph MC,
Engelholm SA and Høgdall C: A novel index for preoperative,
non-invasive prediction of macro-radical primary surgery in
patients with stage IIIC-IV ovarian cancer-a part of the Danish
prospective pelvic mass study. Tumour Biol. 37:12619–12626.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Petrillo M, Vizzielli G, Fanfani F,
Gallotta V, Cosentino F, Chiantera V, Legge F, Carbone V, Scambia G
and Fagotti A: Definition of a dynamic laparoscopic model for the
prediction of incomplete cytoreduction in advanced epithelial
ovarian cancer: Proof of a concept. Gynecol Oncol. 139:5–9.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Son HM, Kim SH, Kwon BR, Kim MJ, Kim CS
and Cho SH: Preoperative prediction of suboptimal resection in
advanced ovarian cancer based on clinical and CT parameters. Acta
Radiol. 58:498–504. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shah JS, Gard GB, Yang J, Maidens J,
Valmadre S, Soon PS and Marsh DJ: Combining serum microRNA and
CA-125 as prognostic indicators of preoperative surgical outcome in
women with high-grade serous ovarian cancer. Gynecol Oncol.
148:181–188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Arits AH, Stoot JE, Botterweck AA, Roumen
FJ and Voogd AC: Preoperative serum CA125 levels do not predict
suboptimal cytoreductive surgery in epithelial ovarian cancer. Int
J Gynecol Cancer. 18:621–628. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kang S, Kim TJ, Nam BH, Seo SS, Kim BG,
Bae DS and Park SY: Preoperative serum CA-125 levels and risk of
suboptimal cytoreduction in ovarian cancer: A meta-analysis. J Surg
Oncol. 101:13–17. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Muallem MZ, Parashkevova A, Almuheimid J,
Richter R, Diab Y, Braicu EI and Sehouli J: Preoperative CA-125
values as a predictive factor for the postoperative outcome in
primary serous ovarian cancer. Anticancer Res. 37:3157–3161.
2017.PubMed/NCBI View Article : Google Scholar
|
